If ovarian cancer recurs within 6 months following initial chemotherapy treatment with Taxol and Carboplatin, it is called a “platinum-resistant” recurrence. This means that treatment with platinum salts has not been effective, and a change in medication will be required to treat the relapse.

If the recurrence occurs after 6 months (or 12 months) after stopping standard treatment, there is a high probability that the treatment will require a combination of chemotherapy agents with platinum salts, as the recurrence is likely to be “platinum sensitive.”

Among the main chemotherapy drugs used to treat this type of cancer, there are mainly associations between a platinum salt And a Taxane. For example, Carboplatin with Paclitaxel (Taxol), which can be administered every three weeks or weekly according to the protocol in place.

This cancer forms in the tissue of the cervix, the lower, narrow part of the uterus. It is usually caused by a persistent infection by certain types of human papillomavirus (HPV), a sexually transmitted infection.

Lynch syndrome : This hereditary cancer predisposition syndrome is caused by mutations in DNA repair genes, such as MLH1, MSH2, MSH6, and PMS2. Women with Lynch syndrome have an increased risk of developing endometrial cancer.

Mutation PIK3CA : This mutation is frequently observed in endometrial cancer. PIK3CA mutations activate the PI3K/Akt/mTOR signaling pathway, which promotes the growth and survival of cancer cells.

Amplification ofHER2 : It has been observed in certain subtypes of endometrial cancer. This genetic alteration can lead to excessive activation of the HER2 signaling pathway, promoting tumor growth.

Knowledge of these mutations can guide the choice of treatments followed and clinical trials in which to participate.